Over 100 California Auctions End Tomorrow 08/12 - Bid Now
Over 1400 Total Lots Up For Auction at Three Locations - TX 08/16, TX 08/25, NY 08/30

OneOncology unveils data demonstrating increased utilization of genomic and biomarker testing at community cancer centers

Press releases may be edited for formatting or style | September 28, 2021 Rad Oncology
NASHVILLE, Tenn., Sept. 27, 2021 /PRNewswire/ -- OneOncology, the national platform for independent community oncology practices, and Genentech, a member of the Roche Group, presented data in two abstracts at the 2021 ASCO Quality Care Symposium examining genomic profiling and biomarker testing patterns in community oncology centers, as part of their multi-year strategic research partnership.

OneOncology and Genentech present data examining genomic profiling and biomarker testing patterns in community oncology centers.

Biomarker and next generation sequencing are the backbone of personalized treatments in oncology.

Source-Ray, Inc. - Innovations In Portable X-Ray

SRI is a leading Developer, Manufacturer & Supplier of Innovative Portable Imaging Equipment. We offer Lightweight, Agile, Easy to Maneuver Portable X-Ray Systems ideal for maneuvering in tight spaces. Call us at 631-244-8200

Bringing personalized cancer treatment to patients in community cancer centers requires biomarker and next generation sequencing (NGS) to identify actionable mutations and improve the time to targeted treatment. Thus, understanding testing patterns at different sites of care is an important component of increasing patient access to innovative targeted therapies for some advanced cancers.

"Biomarker and next generation sequencing are the backbone of personalized treatments in oncology," said Lee Schwartzberg, MD, Chief Medical Officer, OneOncology. "Understanding current testing patterns and strategies to increase their uptake is a vital component to bring precision medicine to oncology practices across the country. These research presentations identify an important baseline for how the physicians on the OneOncology platform are bringing advanced diagnostics to their clinic and how we can improve future utilization."

One real-world data (RWD) study evaluated NGS testing patterns for advanced non-small cell lung cancer and metastatic breast cancer at four OneOncology practices that use Flatiron Health's OncoEMR® electronic health record (EHR).

At the four OneOncology sites in question, 63 percent of patients (2,045 of 3,221) with non-small cell lung cancer received NGS with or without other genetic profile testing compared to 46 percent of patients (13,681 of 29,572) in the broader nationwide Flatiron EHR-derived de-identified NSCLC database. For metastatic breast cancer, the findings were 40 percent (513 of 1,295) as compared to 20 percent (2,458 of 12,175).

While adoption of NGS differed by cancer type and NGS testing rates increased over time in both advanced cancers, the data showed OneOncology had a higher NGS uptake with a shorter time to testing in metastatic breast cancer, possibly related to their network-wide strategy recommending NGS testing at diagnosis of advanced disease. Researchers said further studies are needed to improve the actionability of NGS testing to foster personalized treatment decisions.

You Must Be Logged In To Post A Comment